Radiopharm Theranostics Ltd

Radiopharm Theranostics is a clinical-stage biotech company revolutionizing cancer care through the development of first-in-class radiopharmaceuticals. The company is advancing a pipeline of distinct radiopharmaceutical technologies for novel oncology targets—avoiding "me-too" targets like Prostate-Specific Membrane Antigen (PSMA), Fibroblast Activation Protein (FAP) or Somatostatin Receptor 2 (SSTR2).